In the I-SPY2 neoadjuvant breast cancer trial, functional tumor volume (FTV) derived from dynamic contrast-enhanced MRI serves as a key marker. Participants in I-SPY2 have the option to “de-escalate” therapy if achievement of pathological complete response (pCR) is highly likely at inter-regimen time point. A model combining FTV-based predictive probabilities with inter-regimen core-biopsy pathology is central to select candidates for this option. This retrospective study compared the performance of longitudinal FTVs in predicting pCR between optimal and non-optimal FTV segmentation groups. The results suggest that improvements to FTV segmentation can improve FTV’s ability to provide predictive guidance for treatment de-escalation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords